未分化胰腺癌显示肿瘤细胞PD-L1表达的频率和程度增加。
Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells.
作者信息
Lehrke Heidi D, Graham Rondell P, McWilliams Robert R, Lam-Himlin Dora M, Smyrk Thomas C, Jenkins Sarah, Dong Haidong, Zhang Lizhi
机构信息
Department of Laboratory Medicine and Pathology.
Department of Oncology.
出版信息
Am J Clin Pathol. 2017 Nov 2;148(5):441-449. doi: 10.1093/ajcp/aqx092.
OBJECTIVES
Programmed death ligand 1 (PD-L1) expression in pancreatic ductal adenocarcinoma (PDA) has been described, but unselected PDAs have shown limited clinical responsiveness to anti-programmed death 1 (PD-1)/PD-L1 therapy.
METHODS
We studied 24 cases of undifferentiated pancreatic carcinoma (UPC) using immunohistochemistry for PD-L1 (E1L3N clone), CD3, CD20, CD68, and DNA mismatch repair proteins in this study. Slides were scored for extent of PD-L1 expression on tumor cells and tumor-infiltrating immune cells.
RESULTS
PD-L1 expression was more frequent in UPCs than in PDAs (63% vs 15%, P < .01). The extent of PD-L1 expression was greater in UPCs, with 13 (87%) of 15 cases containing 10% or more positive tumor cells compared with three of seven PDAs (P = .05). Both tumor groups showed similar numbers of tumor-infiltrating T cells, B cells, and macrophages.
CONCLUSIONS
UPC is enriched for PD-L1 expression in frequency and extent, relative to conventional PDA. Anti-PD-1/PD-L1 agents may represent a valuable therapeutic approach for this subset of highly aggressive pancreatic carcinoma.
目的
已对胰腺导管腺癌（PDA）中程序性死亡配体1（PD-L1）的表达进行了描述，但未经选择的PDA对抗程序性死亡1（PD-1）/PD-L1治疗的临床反应有限。
方法
在本研究中，我们使用免疫组织化学方法检测了24例未分化胰腺癌（UPC）中PD-L1（E1L3N克隆）、CD3、CD20、CD68和DNA错配修复蛋白的表达情况。对肿瘤细胞和肿瘤浸润免疫细胞上PD-L1表达的程度进行评分。
结果
UPC中PD-L1表达比PDA更常见（63%对15%，P <.01）。UPC中PD-L1表达程度更高，15例中有13例（87%）含有10%或更多的阳性肿瘤细胞，而7例PDA中只有3例（P =.05）。两组肿瘤中肿瘤浸润性T细胞、B细胞和巨噬细胞的数量相似。
结论
相对于传统PDA，UPC在PD-L1表达的频率和程度上更高。抗PD-1/PD-L1药物可能是这种高度侵袭性胰腺癌亚型的一种有价值的治疗方法。
Zotero 插件